SNG Stock Overview
Synairgen plc discovers and develops drugs for respiratory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Synairgen plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.046 |
| 52 Week High | UK£0.11 |
| 52 Week Low | UK£0.03 |
| Beta | -2.37 |
| 11 Month Change | 0.54% |
| 3 Month Change | 20.10% |
| 1 Year Change | -29.04% |
| 33 Year Change | -97.47% |
| 5 Year Change | -39.28% |
| Change since IPO | -97.02% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation
Dec 09
Here's Why We're Watching Synairgen's (LON:SNG) Cash Burn Situation
Aug 24Is Synairgen (LON:SNG) In A Good Position To Invest In Growth?
Apr 29Companies Like Synairgen (LON:SNG) Could Be Quite Risky
Dec 27We're A Little Worried About Synairgen's (LON:SNG) Cash Burn Rate
Sep 13Companies Like Synairgen (LON:SNG) Could Be Quite Risky
May 31Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation
Feb 06We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely
Oct 21We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely
Mar 29How Much Of Synairgen plc (LON:SNG) Do Institutions Own?
Dec 14Shareholder Returns
| SNG | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -3.9% | -5.2% | 0.8% |
| 1Y | -29.0% | -20.1% | 6.6% |
Return vs Industry: SNG underperformed the UK Biotechs industry which returned -20.1% over the past year.
Return vs Market: SNG underperformed the UK Market which returned 6.6% over the past year.
Price Volatility
| SNG volatility | |
|---|---|
| SNG Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: SNG's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: SNG's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 36 | Richard Marsden | www.synairgen.com |
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Synairgen plc Fundamentals Summary
| SNG fundamental statistics | |
|---|---|
| Market cap | UK£9.32m |
| Earnings (TTM) | -UK£6.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs SNG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNG income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£6.92m |
| Earnings | -UK£6.92m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SNG perform over the long term?
See historical performance and comparison